Profund Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Profund Advisors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,660	Closed	-$517K	–	1215
2026 Q1	$517K	Buy	25,660 +1,268	+5%	+$20.4K	0.02%	540
2025 Q4	$394K	Buy	24,392 +11,779	+93%	+$156K	0.01%	696
2025 Q3	$154K	Buy	12,613 +2,593	+26%	+$35.8K	0.01%	1014
2025 Q2	$113K	Buy	+10,020	New	+$123K	﹤0.01%	956
2025 Q1	–	Sell	-10,762	Closed	-$91.2K	–	1050
2024 Q4	$91.2K	Buy	+10,762	New	+$111K	﹤0.01%	1075

Other funds holding KALV

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Profund Advisors's KALV Position: Q2 2026 in Review

Profund Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 25,660 shares — an estimated $517K sold.

Profund Advisors first reported a position in KALV in Q4 2024 and held it in 5 quarters. The position peaked at $517K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Profund Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Profund Advisors sold 25,660 KalVista Pharmaceuticals shares in Q2 2026, an estimated $517K.
Profund Advisors first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 5 quarters.
Profund Advisors's KalVista Pharmaceuticals position peaked at $517K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.